Tiziana Life Sciences plc: Publication of Research Note

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1

Go here to see the original:
Tiziana Life Sciences plc: Publication of Research Note

VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020.

Here is the original post:
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

Read the original here:
Novo Nordisk A/S – Share repurchase programme

Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

Read the rest here:
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science

Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases

View original post here:
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science

JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that positive results from the two pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the Journal of the American Medical Association (JAMA) Dermatology.

See more here:
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION

RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION

Here is the original post:
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION

Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that a post hoc analysis of the Phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETINA 2020 Virtual.

More here:
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020

Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.

Original post:
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.

View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference